AI summary by TwinMind
The Chinese Hamster Revolutionized Medicine
Asianometry
20m 12s
World's Top-Selling Drugs and Antibody Dominance
- 2023 top-selling drug: Keytruda (antibody) - $25 billion sales, $27 billion projected 2024
- 5 of top 10 bestselling drugs in 2023 were antibodies
- Antibody therapies revolutionized medicine but manufacturing remained challenge
Antibody Fundamentals and Early History
- Antibodies: Y-shaped proteins that bind foreign bodies, signal white blood cells for destruction
- Also called immunoglobulins, produced by B lymphocytes/B cells from bone marrow
- Named by Nobel winner Paul Ehrlich (1897) - originally "anti-körper" placeholder term
- Early serum therapy method: inoculate animals (horses), harvest serum, purify for treatment
- Emil von Behring won 1901 Nobel for diphtheria antitoxin (saved 50,000 children/year)
- Problems: unreliable activity, serum sickness, contamination risks
- 1901 tetanus contamination killed dozen children
- Linus Pauling attempted artificial antibodies (1940s) but couldn't replicate results
Monoclonal Antibody Breakthrough
- Monoclonal = exact copies of single antibody (single clones)
- 1960s research on myelomas (plasma cell cancers) - infinite reproduction, faulty antibody production
- Cesar Milstein & George Köhler breakthrough using Sendai virus
- Fused mouse myeloma cells with mouse B cells creating hybridomas
- Combined cancer cell longevity with B cell antibody production
- Worked on first try, won 1984 Nobel Prize
- Milstein never patented method (miscommunication or didn't see commercial potential)
Early Commercial Challenges
- 1980 press called monoclonal antibodies "Magic Bullets" - set unrealistic expectations
- First treatment approved 1986: Muromonab-CD3 (OKT3) for kidney transplant rejection
- Major problems with mouse-derived antibodies:
- 5-10% patients suffered complications, some severe allergic shock
- Genetically unstable hybridomas
- Short-lived in human body, required large frequent doses
- Human immune system didn't recognize mouse antibodies
- 1980s London: millions invested in startups, most failed
- 15 years after 1975 Nobel discovery yielded only one US approved treatment
- Industry exec: "molecular snake oil"
Chinese Hamster Laboratory History
- Chinese hamster: small rodent from northern China/Mongolia, grayish-brown, large scrotum
- 1919: Dr. E.T. Tseh (Peking Union Medical College) first used for pneumococcus research
- Considered agricultural pest but vulnerable to human diseases
- Problem: wouldn't breed in captivity, solitary and aggressive
- Late 1920s Harvard failed to breed 150 hamsters despite building basement burrows
The Great Hamster Escape (1948)
- Chinese Civil War threatened hamster supply
- December 6, 1948: Dr. H.C. Chou sent 20 hamsters (10 male, 10 female) to Dr. Robert Watson
- Watson fled Nanjing as Communist forces approached across Yangtze River
- 5:45 AM escape in ice-cold rain with brandy, prayers, Colt .45
- 11-hour drive to Shanghai avoiding mudslides and Communist troops
- Took last Pan Am flight to US
- April 1949: People's Liberation Army conquered Nanjing, People's Republic declared
- Watson brought hamsters to Victor Schwentker (rodent breeder, New York)
- Communist Party later condemned Watson to death for alleged germ warfare
- Dr. Chou convicted, sent to re-education camp, committed suicide with wife 1966
CHO Cell Line Development
- Schwentker successfully bred hamster colony
- 1954: George Yerganian discovered low chromosome count ideal for genetic research
- Random genetic quirk created diabetic hamster lineage useful for diabetes research
- 1957: Theodore Puck (University of Colorado) developed immortal cell lines
- Extracted cells from single female hamster ovary, cultivated 10+ months
- Created famous Chinese Hamster Ovary (CHO) K1 line
- 1960s-1970s: CHO cells known for big chromosomes, hardy cultures, identifiable mutations
Genentech and Protein Production Revolution
- 1976: Roberts Swanson (VC) and Herbert Boyer (UCSF biochemist) founded Genentech
- Boyer pioneered recombinant DNA techniques
- Successfully used E. coli for human insulin and growth hormone
- E. coli failed for complex proteins like TPA (blood clot enzyme) and hepatitis B vaccine
- Problem: E. coli couldn't perform glycosylation (sugar attachment for protein folding)
- Needed more sophisticated "biofactory" for complex proteins
DHFR Gene Amplification System
- 1976: Stanford student Fred Alt discovered CHO cell trick with methotrexate
- Methotrexate kills cancer cells by blocking DHFR enzyme
- Cells develop resistance by rapidly amplifying DHFR gene
- Process: Delete DHFR genes from CHO K1 cells, introduce desired protein gene linked to DHFR
- Cells rapidly uptake and amplify both genes to survive methotrexate treatment
- Result: CHO cells mass-producing desired proteins
Commercial Success and Humanization
- 1987: Genentech set up 10,000L vats of CHO cells producing TPA at scale
- Final step: humanize antibodies by reducing non-human sequences
- H-score developed for judging sequence humanness
- 1997: Genentech/IDEC launched Rituximab for autoimmune disease and cancer
- 1998: FDA approved Trastuzumab (Herceptin) for aggressive breast cancer
- Revolutionized treatment of former death sentence
- Advocates forced FDA fast-tracking due to successful early trials
- Remains gold standard for HER2+ breast cancer
- Both produced in South San Francisco facility using CHO cells
- 2023: Legacy production center closed, 265 layoffs
Current Dominance and Future
- CHO platform dominates antibody/recombinant protein mass production
- 2014-2018: 71 new pharmaceuticals introduced, 80%+ manufactured by CHO cells
- E. coli distant second choice
- FDA familiarity reduces regulatory uncertainty
- 30 years fine-tuning: high yields, growth rates
- Production costs fell from $110,000/gram to ~$100/gram
- Biotech VCs won't back monoclonal antibody therapies made outside CHO platform
Manufacturing Challenges and Future Prospects
- Gene therapies like Lentmeldi cost $4.5 million/dose due to lack of scalable manufacturing
- Each gene therapy essentially custom-made like Lamborghini
- Antibody-drug conjugates emerging: "laser-guided chemotherapy"
- Use specific antibodies to deliver warheads directly to cancer cells
- Antibodies haven't reached peak potential despite dominating top 10 drugs
